Results 111 to 120 of about 171,826 (215)

Improving medication availability through mobile wallets and pooled community funds: results from the MoPuleesa hypertension intervention in rural Uganda. [PDF]

Health Policy Plan
Subramonia Pillai V, Favaretti C, Basenero A, Ntambara JB, Wesva I, Jonathan KM, Munana R, Cazier J, Bärnighausen T, Schwab J, Wachinger J, Kalyesubula R, McMahon SA, Sudharsanan N.   +13 more
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Brain macrostructure correlates of financial altruism in older adults without dementia. [PDF]

Brain Imaging Behav
Fenton L, Weissberger GH, Salminen LE, Samek A, Noriega-Makarskyy DT, Molinare CP, Williams J, Oyen E, Kim P, Axelrod J, Mosqueda L, Yassine H, Han SD.   +12 more
europepmc   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Corrigendum to "Modeling temporal self-continuity and its association with temporal discounting" [Personality and Individual Differences 246 (2025) 113354]. [PDF]

Pers Individ Dif
Lu Y, Rutt JL, Thomas M, Löckenhoff CE.
europepmc   +1 more source

The Effectiveness and Civilian Perceptions of E-Money

Proceedings of the 2nd International Research Conference on Economics and Business, 2018
Bagus Shandy Narmaditya, Dwi Wulandari, Hanum Rida Almira   +2 more
openaire   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Money and Microbes: A Global Systematic Review and Meta-Analysis of Currency Contamination. [PDF]

Environ Health Insights
Appiah PO, Odoom A, Tetteh-Quarcoo PB, Donkor ES.   +3 more
europepmc   +1 more source

A methodological comparative analysis of monetary policy and trade openness on economic growth in West Africa: Does language play a role? [PDF]

PLoS One
Boateng SA, Enimil B, Takyi-Danquah E.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source